Sirio Pharma Co. Ltd., a global contract manufacturer, will now have U.S. based gummy manufacturing capabilities at the site of daughter company Best Formulations.
 
Through the integration of Best Formulations into its business, the CDMO can now offer localized manufacturing in three continents.
 
Best Formulations is on track to achieve full operational readiness by the end of October 2023. The new gummy capabilities include a dedicated R&D lab, an automated production line, and bottle packaging solution. The automated starch-free gummy line can produce a variety of gummies, including gelatin-based, pectin-based, and gelatin-pectin combinations.
 
The onsite R&D lab features pilot-scale equipment, including a gummy depositor that can be seamlessly scaled up into the production line. The pilot-scale equipment provides the ability to produce samples for evaluation on equipment that closely mirrors the production equipment, helping to expedite time to market.
 
Best Formulations will focus on delivering exceptional texture, flavors, and colors. The focus will further extend to developing sugar-free and plant-based options. The company’s team will be able to support customers from concept development through commercialization.
 
The site will also feature turnkey bottle packaging solutions, with the aim of providing flexible and customized packaging options that align with customers’ specific preferences.
 
“We are thrilled to introduce our advanced gummy manufacturing capabilities,” said Edward Shneyvas, head of R&D of Americas at Sirio Pharma, and chief scientific officer at Best Formulations. “With our expertise in delivering tailored solutions, we remain committed to driving innovation and delighting our customers.”